HOME >> BIOLOGY >> NEWS
FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections

Schering-Plough Corporation (NYSE: SGP) today announced that the U.S. Food and Drug Administration (FDA) has approved the once-daily, broad-spectrum antibiotic AVELOX (moxifloxacin HCl) for a new use the treatment of complicated intra-abdominal infections (cIAI) in adults. AVELOX is the only marketed fluoroquinolone antibiotic approved by the FDA as monotherapy to treat this indication. The FDA approval to treat cIAI is the sixth indication for AVELOX.

AVELOX, available in tablet and intravenous (I.V.) formulations, was developed by Bayer Pharmaceuticals Corporation and is marketed in the United States by Schering-Plough.

Intra-abdominal infections are caused by disease, trauma or surgery in the abdomen that cause bacteria to leak from the gastrointestinal tract into adjacent tissue there are approximately 3.5 million cases in the United States each year, with many patients contracting the infection secondary to appendicitis. [1]

"The FDA approval of AVELOX to treat complicated intra-abdominal infections is welcome news, providing doctors with an effective treatment option for their patients, and giving patients convenient once-daily dosing and an easy transition from I.V. to oral therapy when they leave the hospital," said Joseph S. Solomkin, M.D., professor in the department of surgery and director of research of the division of trauma/critical care at the University of Cincinnati College of Medicine.

With this FDA approval, AVELOX is indicated for the treatment of adults with cIAI, including polymicrobial infections such as abscesses caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron or Peptostreptococcus species.

The FDA approval was based on results from clinical studies in cIAI patients showing that sequential I.V. or oral monotherapy with AVELOX once daily was
'"/>


30-Nov-2005


Page: 1 2

Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New system of wastewater treatment could reduce the size of treatment plants by half
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
11. System to analyze beating heart stem cells could lead to heart attack treatments

Post Your Comments:
(Date:7/29/2014)... New research from scientists at the University of Kent ... inside cells are regulated a breakthrough that could ... A team from Kent,s School of Biosciences uncovered the ... within cells known as actin filaments are ... these actin filaments appear to completely stable, providing a ...
(Date:7/29/2014)... breaking new book that brings together two of the ... the profile of insect fossils through stunning photographs and ... and James E Jepson, details the incredible preservation and ... the scene for what these remarkable fossils can tell ... the future of our planet. Like the mosquito in ...
(Date:7/28/2014)... U.S. Food and Drug Administration (FDA) for other purposes ... inside human cells, including those that cause Legionnaires, disease, ... mBio , the online open-access journal of the ... identifying non-antibiotic drugs that could one day help curb ... the list inhibit the growth of at least three ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2New route to identify drugs that can fight bacterial infections 2
(Date:7/29/2014)... (PRWEB) July 29, 2014 TransVac Solutions, ... linen collection and transport solutions for hospitals, will be ... Healthcare Engineering (ASHE) Annual Conference & Technical Exhibition Aug. ... present its technology for making hospitals cleaner, reducing infection ... over the hospital’s life cycle. Staff will be ...
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready ... The Innovation Center @3401 , a collaborative effort of ... Center to help attract and nurture start-up businesses in ... , The Innovation Center @3401 (ic@3401), which ... is the new home of DreamIt Ventures and ...
(Date:7/29/2014)... July 29, 2014  Sigma-Aldrich Corporation (NASDAQ: ... use, increased its investment in Green Chemistry and donated ... world last year, the Company announced Monday in its ... Changed the World? The report comes ... for being a responsible corporate citizen, including recognition for ...
(Date:7/29/2014)... July 29, 2014 Quorum Review ... has been awarded accreditation by the International ... its Lean Six Sigma Deployment Program. The citation ... improve performance. , Quorum’s Lean Six Sigma program ... Deployment Program designation. The designation is a public ...
Breaking Biology Technology:TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 2Quorum Review IRB Accredited by IASSC for Lean Six Sigma Deployment Program 3
Cached News: